CSIMarket
 
Biolinerx Ltd   (BLRX)
Other Ticker:  
 
 
Price: $3.3400 $0.01 0.300%
Day's High: $3.3873 Week Perf: -4.02 %
Day's Low: $ 3.27 30 Day Perf: -41.44 %
Volume (M): 55 52 Wk High: $ 57.60
Volume (M$): $ 183 52 Wk Avg: $24.59
Open: $3.36 52 Wk Low: $3.24



 Market Capitalization (Millions $) 3,218
 Shares Outstanding (Millions) 963
 Employees 133
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -61
 Cash Flow (TTM) (Millions $) 11
 Capital Exp. (TTM) (Millions $) 0

Biolinerx Ltd
BioLineRx Ltd is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for a wide range of diseases. The company was founded in 2003 and is headquartered in Modi'in, Israel. BioLineRx operates globally with offices in the United States, Europe, and Asia, and is listed on the NASDAQ and Tel Aviv Stock Exchanges.

BioLineRx's focus is on the development of novel, therapeutics for oncology, immunology, and other disease areas, with a particular focus on drugs that target unmet medical needs, including rare and hard-to-treat diseases. The company's pipeline consists of both in-house development programs and collaborations with other leading pharmaceutical and biotech companies.

BioLineRx's lead product candidate, BL-8040, is a novel cancer therapy that targets both cancer stem cells and the tumor microenvironment. It is currently being evaluated in multiple clinical trials for hematological malignancies and solid tumors. The company's other pipeline candidates include novel immunotherapies, gene therapies, and small molecules targeting various cancers, inflammatory and autoimmune diseases, and infectious diseases.

BioLineRx is also actively engaged in collaborations with other leading pharmaceutical and biotech companies, including Novartis, Genentech, Merck, and Roche. These collaborations leverage BioLineRx's expertise in drug discovery and development to advance promising therapeutics through clinical trials and regulatory approval.

The company is committed to leveraging cutting-edge technologies in its drug development programs, including genomics, proteomics, and computational biology. BioLineRx has a strong intellectual property portfolio, with more than 60 patents and patent"},"finish


   Company Address: 2 HaMa?ayan Street Modi?in 7177871
   Company Phone Number: 642-9100   Stock Exchange / Ticker: BLRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
HCM   -4.18%    
IRWD   -18.81%    
JAGX   -8.68%    
RDHL   -3.96%    
REGN   -0.96%    
VRTX   -5.72%    
• View Complete Report
   



Biolinerx Ltd

Biolinerx Ltd Reports Revenue Growth but Widening Shortfall in Fourth Quarter 2023



In the midst of a volatile market, Biolinerx Ltd, a biopharmaceutical company, announced its financial results for the fourth quarter of 2023. The company reported a significant increase in revenue, but also a substantial net shortfall compared to the previous year. We will analyze these results and provide insights into the potential reasons for the company's performance. Additionally, we will discuss Biolinerx Ltd's recent stock performance.
Revenue Growth but Widening Shortfall:
Biolinerx Ltd reported revenues of $4.8 million for the fourth quarter of 2023, a positive sign for the company. However, the news was overshadowed by the announcement of a net shortfall of $-60.61 million, significantly larger than the $-24.951 million reported a year ago. This indicates a concerning downward trend in the company's financial stability.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com